Rezvilutamide Explained

Rezvilutamide,[1] [2] sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer.[3] [4] [5] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. The drug was developed by Jiangsu Hengrui Medicine. Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.

Notes and References

  1. Web site: Rezvilutamide . chemidplus . U.S. National Library of Medicine .
  2. Web site: International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO .
  3. Web site: SHR 3680 . AdisInsight .
  4. Keam SJ . Rezvilutamide: First Approval . Drugs . 83. 2. 189–193. January 2023 . 36630077 . 10.1007/s40265-022-01831-y . 255593586 .
  5. Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, He C, Zhu S, Chong T, Yao X, Wan B . 6 . SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study. . Journal of Clinical Oncology. 38. 6_suppl. 2020. 90 . 10.1200/JCO.2020.38.6_suppl.90. 214027454 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rezvilutamide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.